Videos

Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.
Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2- metastatic breast cancer regarding how long their treatment will last and how it will impact them.
Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2- metastatic breast cancer, citing bone metastasis as the most prevalent.
The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy.
Dr. Valérie Vilgrain discusses SIRT Y-90 and the results of the SARAH trial.
Page 4 of 4
Results 31 - 35 of 35